Associations - EGFR inhibitor

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval J Clin Oncol - 3 days (New B) osimertinib Sensitive : A1 J Clin Oncol - 3d	osimertinib Sensitive: A1 - Approval J Clin Oncol - 3 days osimertinib Sensitive : A1 J Clin Oncol - 3 days - (New B)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval J Clin Oncol - 3 days (New B) osimertinib Sensitive : A1 J Clin Oncol - 3d	osimertinib Sensitive: A1 - Approval J Clin Oncol - 3 days osimertinib Sensitive : A1 J Clin Oncol - 3 days - (New B)
EGFR mutation + TP53 mutation + PTEN mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + PTEN mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 6 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 6d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 6 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 6 days - (New C3)
EGFR mutation + TP53 mutation + BRCA1 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + BRCA1 mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 6 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 6d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 6 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 6 days - (New C3)
EGFR mutation + TP53 mutation + ARID1A mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + ARID1A mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 6 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 6d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 6 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 6 days - (New C3)
EGFR mutation + TP53 mutation + NF1 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + NF1 mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 6 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 6d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 6 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 6 days - (New C3)
EGFR mutation + TP53 mutation + RB1 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + RB1 mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 6 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 6d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 6 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 6 days - (New C3)
EGFR G719A	Non Small Cell Lung Cancer	EGFR G719A	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 6 days (New C4) amivantamab-vmjw Sensitive : C4 IASLC-TTLC 2023 - 6d	amivantamab-vmjw Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 6 days amivantamab-vmjw Sensitive : C4 IASLC-TTLC 2023 - 6 days - (New C4)
RET fusion + TP53 mutation	HER2 Positive Breast Cancer	RET fusion + TP53 mutation	HER2 Positive Breast Cancer	pyrotinib Resistant: C4 – Case Studies Anticancer Drugs - 1 week (New C4) pyrotinib Resistant : C4 Anticancer Drugs - 1wk	pyrotinib Resistant: C4 – Case Studies Anticancer Drugs - 1 week pyrotinib Resistant : C4 Anticancer Drugs - 1 week - (New C4)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	dasatinib + lapatinib Sensitive: D – Preclinical PLoS One - 1 week (New D) dasatinib + lapatinib Sensitive : D PLoS One - 1wk	dasatinib + lapatinib Sensitive: D – Preclinical PLoS One - 1 week dasatinib + lapatinib Sensitive : D PLoS One - 1 week - (New D)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline ASCO-GI 2023 - 2 weeks (New C3) cetuximab + trametinib + dabrafenib Sensitive : A2 ASCO-GI 2023 - 2wk	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline ASCO-GI 2023 - 2 weeks cetuximab + trametinib + dabrafenib Sensitive : A2 ASCO-GI 2023 - 2 weeks - (New C3)
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval Future Oncol - 2 weeks (New B) osimertinib Sensitive : A1 Future Oncol - 2wk	osimertinib Sensitive: A1 - Approval Future Oncol - 2 weeks osimertinib Sensitive : A1 Future Oncol - 2 weeks - (New B)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) cetuximab + encorafenib Sensitive : A1 ASCO-GI 2023 - 2wk	cetuximab + encorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks cetuximab + encorafenib Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: A1 - Approval Adv Ther - 2 weeks (New C3) amivantamab-vmjw Sensitive : A1 Adv Ther - 2wk	amivantamab-vmjw Sensitive: A1 - Approval Adv Ther - 2 weeks amivantamab-vmjw Sensitive : A1 Adv Ther - 2 weeks - (New C3)
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label Cancer Lett - 2 weeks (New D) osimertinib Sensitive : C1 Cancer Lett - 2wk	osimertinib Sensitive: C1 - Off-label Cancer Lett - 2 weeks osimertinib Sensitive : C1 Cancer Lett - 2 weeks - (New D)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) pyrotinib + dalpiciclib Sensitive : C2 ASCO-GI 2023 - 2wk	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks pyrotinib + dalpiciclib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS wild-type	Colorectal Cancer	KRAS wild-type	Colorectal Cancer	cetuximab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) cetuximab Sensitive : C2 ASCO-GI 2023 - 2wk	cetuximab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks cetuximab Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression	Colorectal Cancer	EREG overexpression + AREG overexpression	Colorectal Cancer	panitumumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) panitumumab Sensitive : C3 ASCO-GI 2023 - 2wk	panitumumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks panitumumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2wk	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression	Colorectal Cancer	EREG overexpression + AREG overexpression	Colorectal Cancer	cetuximab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) cetuximab Sensitive : C3 ASCO-GI 2023 - 2wk	cetuximab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks cetuximab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
EGFR exon 19 deletion + EGFR C797S	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR C797S	Lung Adenocarcinoma	osimertinib + anlotinib Sensitive: C4 – Case Studies Pharmacol Res - 2 weeks (New C4) osimertinib + anlotinib Sensitive : C4 Pharmacol Res - 2wk	osimertinib + anlotinib Sensitive: C4 – Case Studies Pharmacol Res - 2 weeks osimertinib + anlotinib Sensitive : C4 Pharmacol Res - 2 weeks - (New C4)
EGFR L860R	Lung Adenocarcinoma	EGFR L860R	Lung Adenocarcinoma	osimertinib Sensitive: D – Preclinical Cancer Lett - 2 weeks (New D) osimertinib Sensitive : D Cancer Lett - 2wk	osimertinib Sensitive: D – Preclinical Cancer Lett - 2 weeks osimertinib Sensitive : D Cancer Lett - 2 weeks - (New D)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: A1 - Approval Takeda Press Release - 3 weeks (New A1) mobocertinib Sensitive : A1 Takeda Press Release - 3wk	mobocertinib Sensitive: A1 - Approval Takeda Press Release - 3 weeks mobocertinib Sensitive : A1 Takeda Press Release - 3 weeks - (New A1)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	lapatinib Sensitive: A2 - Guideline Eur J Cancer - 3 weeks (New B) lapatinib Sensitive : A2 Eur J Cancer - 3wk	lapatinib Sensitive: A2 - Guideline Eur J Cancer - 3 weeks lapatinib Sensitive : A2 Eur J Cancer - 3 weeks - (New B)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	erlotinib + vemurafenib Sensitive: C3 – Early Trials Clin Cancer Res - 3 weeks (New C3) erlotinib + vemurafenib Sensitive : C3 Clin Cancer Res - 3wk	erlotinib + vemurafenib Sensitive: C3 – Early Trials Clin Cancer Res - 3 weeks erlotinib + vemurafenib Sensitive : C3 Clin Cancer Res - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib + AB-329 Sensitive: C3 – Early Trials Cancer Med - 3 weeks (New C3) gefitinib + AB-329 Sensitive : C3 Cancer Med - 3wk	gefitinib + AB-329 Sensitive: C3 – Early Trials Cancer Med - 3 weeks gefitinib + AB-329 Sensitive : C3 Cancer Med - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + MEDI9447 Sensitive: C3 – Early Trials J Thorac Oncol - 3 weeks (New C3) osimertinib + MEDI9447 Sensitive : C3 J Thorac Oncol - 3wk	osimertinib + MEDI9447 Sensitive: C3 – Early Trials J Thorac Oncol - 3 weeks osimertinib + MEDI9447 Sensitive : C3 J Thorac Oncol - 3 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
EGFR expression	Lung Non-Small Cell Squamous Cancer	EGFR expression	Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval necitumumab Sensitive : A1	necitumumab Sensitive: A1 - Approval necitumumab Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	lapatinib Sensitive: A1 - Approval lapatinib Sensitive : A1	lapatinib Sensitive: A1 - Approval lapatinib Sensitive : A1
HER-2 overexpression	Hormone Receptor Negative Breast Cancer	HER-2 overexpression	Hormone Receptor Negative Breast Cancer	trastuzumab + lapatinib Sensitive: A1 - Approval trastuzumab + lapatinib Sensitive : A1	trastuzumab + lapatinib Sensitive: A1 - Approval trastuzumab + lapatinib Sensitive : A1
HER-2 overexpression	Breast Cancer	HER-2 overexpression	Breast Cancer	lapatinib Sensitive: A1 - Approval lapatinib Sensitive : A1	lapatinib Sensitive: A1 - Approval lapatinib Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
EGFR expression	Colorectal Cancer	EGFR expression	Colorectal Cancer	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
KRAS Q61	Colorectal Cancer	KRAS Q61	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS A146	Colorectal Cancer	KRAS A146	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	aumolertinib Sensitive: A1 - Approval aumolertinib Sensitive : A1	aumolertinib Sensitive: A1 - Approval aumolertinib Sensitive : A1
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + erlotinib Sensitive: A1 - Approval bevacizumab + erlotinib Sensitive : A1	bevacizumab + erlotinib Sensitive: A1 - Approval bevacizumab + erlotinib Sensitive : A1

EGFR inhibitor

EGFR inhibitor

Associations(1945)

Associations
(1945)